Williams Paul T
Molecular Biophysics & Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA.
Int J Cardiol. 2021 Mar 15;327:185-192. doi: 10.1016/j.ijcard.2020.11.070. Epub 2020 Dec 6.
"Quantile-dependent expressivity" occurs when the effect size of a genetic variant depends upon whether the phenotype (e.g. cholesterol) is high or low relative to its distribution. We have previously shown that the effect of a 52-SNP genetic-risk score was 3-fold larger at the 90th percentile of the total cholesterol distribution than at its 10th percentile. The objective of this study is to assess quantile-dependent expressivity for total cholesterol in 7006 offspring with parents and 2112 sibships from Framingham Heart Study.
Quantile-specific heritability (h) was estimated as twice the offspring-parent regression slope as robustly estimated by quantile regression with nonparametric significance assigned from 1000 bootstrap samples.
Quantile-specific h increased linearly with increasing percentiles of the offspring's cholesterol distribution (P = 3.0 × 10), i.e. h = 0.38 at the 10th percentile, h = 0.45 at the 25th percentile, h = 0.52 at the 50th, h = 0.61 at the 75th percentile, and h = 0.65 at the 90th percentile of the total cholesterol distribution. Average h decreased from 0.55 to 0.34 in 3564 offspring who started cholesterol-lowering medications, but this was attributable to quantile-dependent expressivity and the offspring's 0.94 mmol/L average drop in total cholesterol. Quantile-dependent expressivity likely explains the reported effect of the CELSR2/PSRC1/SORT1 rs646776 and APOE rs7412 gene loci on statin efficacy. Specifically, a smaller genetic effect size at the lower (post-treatment) than higher (pre-treatment) cholesterol concentrations mandates that the trajectories of the genotypes cannot move in parallel when cholesterol is decreased pharmacologically.
Cholesterol concentrations exhibit quantile-dependent expressivity, which may provide an alternative interpretation to pharmacogenetic and nutrigenetic interactions.
当基因变异的效应大小取决于表型(如胆固醇)相对于其分布是高还是低时,就会出现“分位数依赖表达性”。我们之前已经表明,在总胆固醇分布的第90百分位数处,一个包含52个单核苷酸多态性(SNP)的遗传风险评分的效应比在第10百分位数处大3倍。本研究的目的是评估来自弗雷明汉心脏研究的7006名有父母的后代和2112个同胞对中总胆固醇的分位数依赖表达性。
分位数特异性遗传力(h)被估计为后代-父母回归斜率的两倍,通过分位数回归稳健估计,并从1000次自助抽样中分配非参数显著性。
分位数特异性h随着后代胆固醇分布百分位数的增加而线性增加(P = 3.0×10),即在总胆固醇分布的第10百分位数处h = 0.38,第25百分位数处h = 0.45,第50百分位数处h = 0.52,第75百分位数处h = 0.61,第90百分位数处h = 0.65。在开始使用降胆固醇药物的3564名后代中,平均h从0.55降至0.34,但这归因于分位数依赖表达性以及后代总胆固醇平均下降0.94 mmol/L。分位数依赖表达性可能解释了关于CELSR2/PSRC1/SORT1 rs646776和APOE rs7412基因座对他汀类药物疗效的报道效应。具体而言,在较低(治疗后)胆固醇浓度下比在较高(治疗前)胆固醇浓度下更小的遗传效应大小意味着当通过药物降低胆固醇时,基因型的轨迹不能平行移动。
胆固醇浓度表现出分位数依赖表达性,这可能为药物遗传学和营养遗传学相互作用提供另一种解释。